<DOC>
	<DOCNO>NCT00486031</DOCNO>
	<brief_summary>The objective study evaluate long-term safety tolerability treatment balsalazide disodium tablet subject remission ulcerative colitis mildly moderately active UC .</brief_summary>
	<brief_title>Open-Label , Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Balsalazide</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Subject document history UC either remission currently present mildly moderately active UC symptom determine investigator upon subject interview UC symptom , ( e.g. , urgency , bowel frequency , rectal bleeding ) . Additionally , diagnosis UC must confirm past flexible sigmoidoscopy/colonoscopy may include colonic mucosal pathological finding biopsy consistent UC . Subject capable willing comply study procedure . Subject history allergy intolerance aspirin , mesalamine salicylate . Subject participate investigational drug device study , previous balsalazide disodium tablet trial ( i.e. , BZUC3002 BZUC3003 ) , within 30 day enter current study . Subject discontinue previous balsalazide disodium tablet study due study drugrelated AE ( ) , include UC flare associate symptom perceive subject/investigator cause study drug . Subject prior bowel surgery , except appendectomy cholecystectomy . Subject unstable cardiovascular , coagulopathy , pulmonary disease . Regular use nonsteroidal antiinflammatory drug ( NSAIDS ) except cardioprotective ASA ( i.e. , less equal 162 mg ASA per day ) . Subject history human immunodeficiency virus ( HIV ) hepatitis ( B C ) . Subjects history hepatitis B C eligible provide screen LFTs within normal limit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>IBD</keyword>
	<keyword>UC</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>